Methocarbamol API Powder CAS 532-03-6

Methocarbamol API powder is primarily used in the treatment of musculoskeletal disorders as an adjunct to rest and physical therapy to relieve discomfort associated with acute, painful musculoskeletal conditions. Specific indications include sprains, lumbar muscle strain, sciatica, muscle spasms, muscle stiffness, and muscle tension caused by herniated discs. The core application of this active pharmaceutical ingredient is in treating acute muscle spasms requiring short-term relief, particularly for localized muscle pain syndromes caused by sports injuries, improper posture, or chronic strain.The raw material is rapidly absorbed into the bloodstream after oral or intravenous administration, with a plasma half-life maintained for 1 to 2 hours. The drug's binding rate to plasma proteins remains stable in the range of 46% to 50%. It can be used alone in combination with rest and physical therapy programs to relieve muscle pain, or it can be compounded with analgesic raw materials to optimize the finished product prescription. It is suitable for stratified clinical treatment programs for mild to severe muscle spasms and occupies a stable position in the drug chain of orthopedics and pain management.

The core mechanism of action of the Methocarbamol API Powder is to exert its skeletal muscle relaxation and sedation effects through inhibitory effects on the central nervous system (CNS). Although its exact mechanism of action in humans is not fully elucidated, studies suggest that its effects may be primarily attributed to broad CNS inhibition rather than direct action on the skeletal muscle itself. Pharmacological experiments have confirmed that Methocarbamol has no direct effect on the contraction mechanism of skeletal muscle, motor endplates, or nerve fibers, indicating that its site of action is central rather than peripheral. Through central inhibition, this drug can reduce the brain's perception and response to muscle tension, thereby reducing reflexive muscle spasms caused by pain or injury. It is important to note that Methocarbamol may enhance the effects of alcohol and other CNS depressants; patients receiving treatment should avoid dangerous activities requiring mental alertness, such as driving or operating machinery.

In addition, Methocarbamol API Powder may inhibit the effects of anticholinesterase drugs such as pyridostigmine, and should be used with caution in patients with comorbid myasthenia gravis who are receiving anticholinesterase therapy.

Molecular Formula: C11H15NO5
Molecular Weight: 241.24
Melting Point: 93～97℃
Boiling Point: 384.01 °C
Density: 1.2611 g/cm³
PH: 5.0～7.0